Prescient Therapeutics (ASX:PTX) Operating Cash Flow per Share : A$-0.01 (TTM As of Dec. 2024)

View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Operating Cash Flow per Share?

Prescient Therapeutics's operating cash flow per share for the six months ended in Dec. 2024 was A$-0.01. Prescient Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.01.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -14.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 8.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 16.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Prescient Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

ASX:PTX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -17.4 Med: 20 Max: 72.8
Current: -14.5

During the past 13 years, Prescient Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.80% per year. The lowest was -17.40% per year. And the median was 20.00% per year.

ASX:PTX's 3-Year OCF Growth Rate is ranked worse than
77.07% of 1221 companies
in the Biotechnology industry
Industry Median: 9.3 vs ASX:PTX: -14.50

Prescient Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Prescient Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Operating Cash Flow per Share Chart

Prescient Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.01

Prescient Therapeutics Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-	-0.01	-	-0.01	-0.01

Competitive Comparison of Prescient Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Prescient Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Prescient Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Prescient Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (A: Jun. 2023 )	=	Cash Flow from Operations (A: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (A: Jun. 2023 )
	=	-6.191	/	727.527
	=	-0.01

Prescient Therapeutics's Operating Cash Flow per Share for the quarter that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2024 )	=	Cash Flow from Operations (Q: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
	=	-5.789	/	805.320
	=	-0.01

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01

Prescient Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics Headlines

No Headlines